Fennec Pharmaceuticals Inc.FENCNASDAQ
LOADING
|||
Operating Income Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
93.08%
↑ 3036% above average
Average (39q)
2.97%
Historical baseline
Range
High:835.61%
Low:-238.12%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 93.08% |
| Q2 2025 | -238.12% |
| Q1 2025 | 13.49% |
| Q4 2024 | 82.05% |
| Q3 2024 | -3.23% |
| Q2 2024 | -136.67% |
| Q1 2024 | 835.61% |
| Q4 2023 | -83.70% |
| Q3 2023 | 78.49% |
| Q2 2023 | 10.29% |
| Q1 2023 | 14.10% |
| Q4 2022 | 18.37% |
| Q3 2022 | -51.09% |
| Q2 2022 | -38.30% |
| Q1 2022 | 14.22% |
| Q4 2021 | -1.16% |
| Q3 2021 | -6.63% |
| Q2 2021 | 21.63% |
| Q1 2021 | -48.23% |
| Q4 2020 | 42.75% |
| Q3 2020 | -18.60% |
| Q2 2020 | -35.99% |
| Q1 2020 | 2.54% |
| Q4 2019 | -99.60% |
| Q3 2019 | 61.29% |
| Q2 2019 | -79.59% |
| Q1 2019 | 13.69% |
| Q4 2018 | -9.02% |
| Q3 2018 | -6.87% |
| Q2 2018 | -48.80% |
| Q1 2018 | 28.79% |
| Q4 2017 | -15.05% |
| Q3 2017 | -47.80% |
| Q2 2017 | -91.83% |
| Q1 2017 | 32.72% |
| Q4 2016 | -103.19% |
| Q3 2016 | 20.23% |
| Q2 2016 | -55.73% |
| Q1 2016 | 17.60% |
| Q4 2015 | -63.02% |